Latest News
Get real-time updates on the latest news and developments in the pharmaceutical world. Stay informed about new drug launches, research findings, regulatory changes, and industry updates. Explore a wide range of topics and stay connected with the rapidly evolving world of pharma.
Taysha halts gene therapy for rare nerve disease after FDA and Astellas feedback
Astellas has declined the opportunity to exercise an option for an asset from Taysha Gene Therapies. Taysha, facing study design ...
Biocon Biologics’ CEO reveals pricing strategy and device design for Hulio, its Humira biosimilar, in the US market
The competition in the biosimilar arena targeting AbbVie’s blockbuster drug Humira, also known as adalimumab, is heating up. However, for ...
Debbie Allen joins Regeneron and Prevent Blindness to launch the Gr8 Eye Movement and raise awareness of serious retinal diseases
Regeneron is adding a touch of star power to its efforts to promote eye health by enlisting the renowned actress, ...
Revance slashes Daxxify’s price to compete with AbbVie’s Botox in the cosmetic market
Nashville-based company Revance had high hopes for its new cosmetic dermal filler, Daxxify, which boasted a longevity twice that of ...
Novo Nordisk’s semaglutide facility in North Carolina faces FDA scrutiny over quality issues
Novo Nordisk’s shares faced a decline following reports that the FDA had raised concerns about manufacturing issues at the company’s ...
FDA issues guidance on single-trial evidence for drug approval
Biopharmaceutical companies seeking FDA approval based on a single clinical trial must provide comprehensive and transparent data, including both positive ...
Scancell’s DNA vaccine shows promising results in phase 2 trial for skin cancer
Scancell’s shareholders are enjoying a prosperous week as the biotech company’s stock surged by 20%, driven by promising preliminary data ...
Arcturus reports positive results for sa-mRNA COVID boosters in phase 1/2 trial
Amid a shrinking COVID-19 vaccine market, Arcturus Therapeutics is forging ahead with its mRNA candidate, revealing promising early data demonstrating ...
Novo and Lilly’s obesity drugs face barriers of high price and low coverage, survey shows
A recent survey of 100 doctors in the United States who prescribe weight loss medications has revealed that over 75% ...
Humira sales decline as biosimilars gain traction, but physicians remain wary of switching patients
In the race to capture a share of the $20 billion annual revenue generated by AbbVie’s blockbuster biologic, Humira biosimilars ...
Astellas claims positive results for Izervay in geographic atrophy but remains vague on data
Astellas, having recently secured FDA approval for its drug Izervay to treat geographic atrophy (GA), is now in direct competition ...
Guard shares soar as new data show clinical benefit despite missing primary endpoint
Guard Therapeutics is staging a remarkable recovery following a setback in its phase 2 clinical trial for kidney injury treatment. ...
Novartis gives up on tislelizumab, BeiGene’s PD-1 inhibitor approved in Europe
Novartis has terminated its significant cancer immunotherapy collaboration with BeiGene, ending a partnership that had granted Novartis co-development and co-commercialization ...
Biocon appoints Peter Bains as group CEO to lead its global expansion
Biocon has appointed Peter Bains as its new CEO as the company seeks to expand its presence in North America ...
Novo Nordisk partners with Aspen to boost insulin supply in Africa
Novo Nordisk, a prominent player in the diabetes pharmaceutical industry, is taking significant steps to bolster insulin supplies in Africa. ...
Kinnate slashes workforce and pipeline after disappointing clinical data
Kinnate Biopharma, a Californian biotech, is taking significant measures to manage its financial situation after disappointing cancer data results led ...
Pfizer’s tafamidis faces competition from Alnylam and BridgeBio in rare disease market
Alnylam and BridgeBio are poised to enter the highly lucrative transthyretin amyloidosis cardiomyopathy (ATTR-CM) market with the backing of an ...
Catalent hires former Lonza bioscience chief to lead its biologics unit amid CEO departure
In a swift succession of leadership changes at Swiss contract development and manufacturing organization (CDMO) Lonza, David McErlane, the former ...
BOTOX Cosmetic shows promise for neck and lower face rejuvenation in phase 3 trial
Allergan Aesthetics, a subsidiary of AbbVie, has unveiled positive top-line findings from the second out of three Phase 3 clinical ...
Sandoz gets CHMP nod for biosimilar of Herceptin, a drug for HER2+ breast and gastric cancer
Sandoz, a leading global player in generic and biosimilar medications, has received a noteworthy endorsement from the Committee for Medicinal ...
Pharmanovia buys 11 CNS drugs from Sanofi to expand its portfolio of repurposed medicines
Sanofi, in its ongoing effort to streamline its product portfolio, is divesting 11 central nervous system (CNS) medications to Pharmanovia, ...
Motif Neurotech implants tiny device to stimulate brain and treat depression
Neurostimulation has emerged as a promising therapy for alleviating the symptoms of major depressive disorder, even in cases where traditional ...
CEPI funds BioNTech’s mRNA-based mpox vaccine trial with $90 million
BioNTech, the German biotech renowned for its groundbreaking mRNA COVID-19 vaccine, is embarking on clinical trials for an mRNA vaccine ...
Lonza CEO Ruffieux quits after less than a year, chairman steps in
Lonza, the Swiss Contract Development and Manufacturing Organization (CDMO), is once again on the hunt for a new CEO, marking ...
Samsung Biologics expands antibody production deal with Bristol Myers Squibb for $242 million
Samsung Biologics, a leading biopharmaceutical contract manufacturing organization, has strengthened its partnership with Bristol Myers Squibb (BMS) by securing a ...
Anthos’ ABP-959 outperforms Xarelto in preventing bleeding events in phase 2 trial
Blackstone Life Sciences’ substantial $250 million investment in an ex-Novartis drug candidate has yielded yet another positive outcome in its ...
Nobel Prize Winner in Chemistry Joins Acepodia to Develop Novel Cell Therapies for Cancer
Renowned Nobel laureate Carolyn Bertozzi, Ph.D., has joined Acepodia as its Chief Scientific Adviser, marking a significant development in the ...
Novartis commissions art exhibition to raise awareness of rare blood cancers
Novartis has taken a creative approach to raise awareness about rare blood cancers, specifically myeloproliferative neoplasms (MPNs), which impact approximately ...
Enhertu, a Breakthrough Therapy for HER2 Mutant NSCLC, Gets EU Nod
Enhertu (trastuzumab deruxtecan) has received a positive recommendation for approval in the European Union (EU) as a standalone treatment for ...
Quizartinib Gets Green Light in EU for Treating Acute Myeloid Leukemia
Daiichi Sankyo has received a positive recommendation for the approval of quizartinib in the European Union (EU). This recommendation is ...
